SCHEMBL29949243

SCHEMBL29949243

COCC(C)(NC(=O)OC(C)(C)C)c1cccc(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.41
MAPT P10636 1/20 0.39
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.37
SLC6A2 P23975 2/20 0.36
CYP2C19 P33261 2/20 0.36
CHRNA1 P02708 1/20 0.36
CHRNG P07510 1/20 0.36
ITGA5 P08648 1/20 0.36
CHRNB1 P11230 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNB4 P30926 1/20 0.36
SLC6A4 P31645 1/20 0.36
CHRNA3 P32297 1/20 0.36
HRH1 P35367 1/20 0.36
CHRNA7 P36544 1/20 0.36
OPRK1 P41145 1/20 0.36
CHRNA4 P43681 1/20 0.36
SLC6A3 Q01959 1/20 0.36
CHRND Q07001 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25399092 0.87 CTSL (0.42) CTSLMAPTKDM4EHPGDSLC6A2
SCHEMBL26257358 0.87 CTSL (0.42) CTSLMAPTKDM4EHPGDSLC6A2
SCHEMBL29949477 0.87 CTSL (0.42) CTSLMAPTKDM4EHPGDSLC6A2
SCHEMBL25395803 0.86 MAPT (0.39) CTSLMAPTKDM4ESLC6A2CYP2C19
SCHEMBL26965566 0.85 PKM (0.40) MAPTHPGDSLC6A2CYP2C19CHRNA1
SCHEMBL25402190 0.85 RXFP1 (0.46) MAPTALDH1A1SMN1; SMN2GAA
SCHEMBL20117837 0.81 MAPT (0.50) MAPTHPGDCYP2C19ALDH1A1SMN1; SMN2
SCHEMBL24944766 0.78 CTSL (0.42) CTSLMAPTKDM4EHPGDCYP2C19
SCHEMBL19731493 0.78 CTSL (0.42) CTSLMAPTKDM4EHPGDCYP2C19
SCHEMBL25402601 0.77 CTSL (0.48) CTSLKDM4EAKT1IDO1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11945811-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2024-04-02 US disclosed
EP-4313973-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2024-02-07 EP disclosed
US-20230406845-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2023-12-21 US disclosed
WO-2022200162-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACECION PHARMA APS (DK) 2022-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11945811-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 CTSL 3805/4885MAPT 1789/4885KDM4E 1829/4885
US-20230406845-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 CTSL 3759/4885MAPT 2025/4885KDM4E 1291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.